Purdue Research Foundation, The Brigham and Women's Hospital Inc., the University of California Oakland and University of Utah have developed platinum complexes for the treatment of cyanide poisoning.
Fochon Biosciences Ltd. has identified apoptosis regulator Bcl-2 (D103E mutant) inhibitors reported to be useful for the treatment of autoimmune disease and cancer.
Instead of inter partes review (IPR) being a streamlined alternative to costly patent litigation as intended, a precedential decision by the U.S. Circuit Court of Appeals for the Federal Circuit could make appeals of IPR decisions, regardless of their merits, another way to delay competition.
Work at Beijing Earthwise Technology Co. Ltd. has led to the discovery of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.
An Allorion Therapeutics (Guangzhou) Co. Ltd. patent discloses aminoheteroaryl CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.
Celgene Corp. has identified substituted imidazopyrazine compounds characterized as interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) ligands and thus reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
Quinoxaline derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) and/or (E545K mutant) inhibitors have been described in a Black Diamond Therapeutics Inc. patent.
Shanghai Apeiron Biotechnology Co. Ltd. has patented new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
RSS
